前列Ⅱ号治疗良性前列腺增生症的临床观察
|
摘要
目的 探讨前列Ⅱ号治疗良性前列腺增生症的临床疗效。方法 选择80例良性前列腺增生症患者随机分为两组，治疗组40例，口服前列Ⅱ号每次一袋每日2次，对照组40例，口服舍尼通每次一片每日2次。两组均治疗2个月。对治疗前后临床症状、IPSS、QOL的评分情况，治疗前后检测的DRE、最大尿流率、排尿量、残余尿量、前列腺体积等指标进行对照分析。结果 治疗组40例病人，显著改善者15％，中度改善者32.5％，轻度改善者37.5％，总有效率85％；对照组40例病人，显著改善者11.25％，中度改善者22.5％，轻度改善者40％，总有效率73.75％。
Ridit检验分析(P＜0.05)，两组疗效比较有显著性差异。治疗组疗后临床症状、IPSS、QOL、最大尿流率、残余尿量均有明显改善，经t检验分析(P＜0.05)，治疗后两组疗效比较有显著性差异。而DRE、排尿量、前列腺体积治疗后两组经t检验分析(P＞0.05)，疗效比较无显著性差异。结论 前列Ⅱ号对良性前列腺增生症有良好治疗作用，且疗效优于舍尼通。
Objective To observe the clinical effect on benign prostatic
hyperplasia (BPH) treated by Qian Lie Number II. Method In
clinical observation 80 patients were divided averagely into two
groups at random: control group treated with Cernilton and
1freatment group with Qian Lie Number II .The symptoms and
sighs. the remark of IPSS and QOL. Qmax. Vol. prostate
volume and residural urine volume were detected before treatment
and after being treated for two months. Results In the treatment
group, obvious alleviation rate was l 5 O/o, moderate alleviation
;32.5O/O, mild alleviation 37.5%. The total effective rate was 85%:
In the control group, obvious alleviation 1 l .25 %, moderate
alleviation 22. 5 o/O, mild alleviation 40%, the total effective rate was
73 .75 O/O. With Ridit test, the difference between the two groups was
significant(P<0.05), which show that the effect of Qian Lie Number
II is better than the control group in treatment. The symptoms and
sighs' IPSS' QOL' Qmax and residural urine in treatment group
have obvious alleviation after treatment(P<0.05). There was
obvious defference between the two groups after treatment(P<0.05).
:DRE. Vol and prostate volume have no obvious alleviation after
itreatment which have no obvious difference (P>0.05) between the
ltwo groups. Conclusion The Qian Lie Number II can obviously
alleviate the symptoms and signs of The BPH: The results show that
the effect of Qian Lie Nulnber II on the BPH was superior to that
o f C e rn ilto n.
Ridit检验分析(P＜0.05)，两组疗效比较有显著性差异。治疗组疗后临床症状、IPSS、QOL、最大尿流率、残余尿量均有明显改善，经t检验分析(P＜0.05)，治疗后两组疗效比较有显著性差异。而DRE、排尿量、前列腺体积治疗后两组经t检验分析(P＞0.05)，疗效比较无显著性差异。结论 前列Ⅱ号对良性前列腺增生症有良好治疗作用，且疗效优于舍尼通。
Objective To observe the clinical effect on benign prostatic
hyperplasia (BPH) treated by Qian Lie Number II. Method In
clinical observation 80 patients were divided averagely into two
groups at random: control group treated with Cernilton and
1freatment group with Qian Lie Number II .The symptoms and
sighs. the remark of IPSS and QOL. Qmax. Vol. prostate
volume and residural urine volume were detected before treatment
and after being treated for two months. Results In the treatment
group, obvious alleviation rate was l 5 O/o, moderate alleviation
;32.5O/O, mild alleviation 37.5%. The total effective rate was 85%:
In the control group, obvious alleviation 1 l .25 %, moderate
alleviation 22. 5 o/O, mild alleviation 40%, the total effective rate was
73 .75 O/O. With Ridit test, the difference between the two groups was
significant(P<0.05), which show that the effect of Qian Lie Number
II is better than the control group in treatment. The symptoms and
sighs' IPSS' QOL' Qmax and residural urine in treatment group
have obvious alleviation after treatment(P<0.05). There was
obvious defference between the two groups after treatment(P<0.05).
:DRE. Vol and prostate volume have no obvious alleviation after
itreatment which have no obvious difference (P>0.05) between the
ltwo groups. Conclusion The Qian Lie Number II can obviously
alleviate the symptoms and signs of The BPH: The results show that
the effect of Qian Lie Nulnber II on the BPH was superior to that
o f C e rn ilto n.
引文
1． 顾方六：前列腺增生和前列腺癌在中国发病的初步探讨。中华外科杂志，1993,31:323
2． Berry SJ, Coffey DS, Walsh PC, et al: The development of human benigh prostatic hyperplasia with age. J. Urol 1984;132;474
3． Morrison AS: Risk factors for prostatic hypertrophy. Am. J. Epidemiol 1992;135:974
4． Choi J, Edward F, Benson MC. Cellular senescence: A novel mechanism in the development of BPH. J Urol, 1999,161 :Suppl 4,873．
5． Riddle DL. Ageing. A message from the Gonads. Nature, 1999,399:308-309．
6． Hsin H, Kenyon C.Signals from the reproductive system regulate the life span of C.elegans. Nature, 1999, 399: 362-366．
7． Prehn RT. On the prevention and therapy of prostate cancer by androgen administration. Cancer Res, 1999, 59: 4161-4164．
8． 鲍震美，细胞凋亡。中华泌尿外科杂志，1998, 19:751-754．
9． Green DR. Apoptotic pathway: the roads to ruin. Cell, 1998, 94:695-698．
10． Kroerner G, Zamzami N, Susin SA. Mitochondrial control of apoptosis. Immunol Today, 1997,18:44-51．
11． Susin SA, Lorenzo HK, Zamzami N, et al. Molecular characterization of niitochondrial apoptosis-inducing factor. Nature, 1999, 397:441-446．
12． Tamm I, Wang Y, Sausville E, et al. IAP family protein surviving inhibits caspase activity and apoptosis induced by Fas (CD95) , Bax, caspase and anticancer drugs. Cancer Res, 1998, 58:5315-5320．
13． Deveraux QL, Takahashi R, Salvesen GS, et al. X-linked IAP is a direct inhibitor of cell-death protease. Nature, 1997,388:300-304．
14． Marcelli M, Cunning ham GR, Walkup M, et al. Signal pathway activated during apoptosis of the prostate cancer cell lone LNCaP: Over expression of Caspase 7 as a new gene therapy strategy for prostate cancer. Cancer Res, 1999, 59:382-390．
15． Weinartner K, Ben Sasson SA, Stewart R, et al. Endothelial cell proliferation activity in BPH and prostate cancer, an in vitro model for assessment, J Urol, 1998,159:465-470．
16． Folkman J, Is tissue mass regulated by vascular endothelial cells? Prostate as the first evidence. Endocrinology, 1998, 139:441-442．
17． Nelson NJ. Angiogenesis research is on fast forward. J Natl Cancer Inst, 1999,91:820-822．
18． Colao A, Marzullo P, Ferone D, et al. Prostatic hyperplasia: an unknown feature of acromegaly. J Natl Cancer Inst, 1998,83:775-779．
19． Price DT. New concepts in alpha-receptor biology. Office Education of 94th Annual Meeting, AUA, 1999．
20． Kyprianou N, Litvak JP, Borkowski A, et al. Induction of prostate apoptosis by doxazosin in benign prostatic hyperplasia. J Urol, 1998, 159:1810-1815．
21． Lepor H, Williford WO, Barry MJ, et al. The efficacy of terazosin, finasteride of both in benign prostatic hyperplasia. Veterans affairs cooperative studies benign prostatic hyperplasia study group. N Engl J Med, 1996,335:533-539．
22． Hudson PB, Boake R, Trachtenberg J, et al. Efficiency of finasteride is maintained in patients with BPH treated for 5 years. Urology, 1999,53:690-695．
23． Me Connell JD, Bruskewitz R, Walsh P, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med, 1998,338:557-563．
24． Reddy PK, Wasserman NA, Berg P Zhang G, Kapoor DA: Patient selection predicts out-come following balloon dilatation of Prostate [abstract], J Urol 1991;145:362
25． Reddy PK, Wasserman NA, Gfameda F, Casfaneda-Zuniga WR: Balloon dilatation of the Prostate for treatment of benign hyperplasia. Urol Clin North Am 1998;15:529-535
26． Kitagiwa M, Furuse H, Fukuta K, et al. Int J Urol, 1998;5(2) : 152-156
27． Fabian KM: The intraprostatic partial catheter (Urologial spiral) in German.
Urology [A]1980;19:236-238
28．蔡淦：癃闭。中医内科学 张伯臾主编，上海：上海科学技术出版社 1985；239-244
29．Schneider HJ，植物类药物治疗良性前列增生 UrolB，1994，34：96[德]
30．Patevilch D，仙人掌治疗前列腺肥大，J Herb Spie Medplant，1993，2(1)：45
31．可用来治疗良性前列腺肥大的没药属植物提取物 [英]CPI(B)，1994，(9401)：98
32．用于治疗前列腺肥大的蓝棕属植物提取物[英] CPI(B)，1994，(9344)：103
33．何清湖，尿癃康对大鼠前列腺增生的影响。湖南中医药导报，1997，3(2-3)：61
34．余志红，复方前列宝抑制前列增生及抗炎作用的研究。数理医学杂志，1995，8(2)：137
35．彭培初，复方琥角片治疗前列腺增生症的临床实验研究。上海中医药杂志，1995，(1)：1
36．黄树刚，中药治疗前列腺肥大94例的性激素变化。南京中医学院学报，1994，10(2)：10
37．黄自强，金利油抑制前列腺增生及抗炎作用。中成药，1991，13(6)：27
38．杨文凯，前列宁对前列腺增生的影响及其抗炎作用的研究。中草药，1991，22(6)：261
39．宋杰云，消疬注射液的实验研究。中西医结合杂志，1990，(10)：616
40．柴瑞霁，柴浩然治疗前列腺肥大并发尿潴留的经验。山西中医，1995，11(3)：1
41．方铁生，虚实分证论治疗前列腺增生症150例。南京中医药大学学报，1997，13(4)：206
42．陈万年，从痰论证前列腺增生症57例。山东中医杂志，1995，14(10)：446
43．孙隼修，前列腺肥大从痰论治五法。江苏中医，1995，16(9)：15
44．张文林，活血化瘀法治疗前列腺增生及急性尿潴留258例，辽宁中医杂志，1995，22(6)：263
45．马华，癃闭通治疗老年前列腺增生临床疗效观察。中医药研究，1996，(4)：30
46．陈志强，补肾祛淤疗法治疗前列腺增生症82例。新中医，1995，(2)：19
47．王劲松，自拟癃闭汤治疗前列腺增生症50例。国医论坛，1997，12(1)：32
48．张云程，中药治疗前列腺增生症90例。成都中医学院学报，1991，(3)：16
49．吴敬农，“补敛提汤”治疗老年前列腺肥大症64例。江苏中医，1996，17(1)：17
50．朱晓明，益气导水汤治疗前列腺增生症40例。湖南中医学院学报，1996，16(2)：29
51．牛宝生，前列舒煎治疗前列腺增生症68例。河南中医，1997，17(4)：223
52．张庆好，启癃汤治疗老年前列肥大55例。新中医，1995，27(2)：23
53．石户则孝等。汉方最新治疗，1998：7(3)：253-258
54．关口由纪等。汉方最新治疗，1997；6(3)：283-286
55．王敬善，前列丸治疗前列腺增生症和慢性前列腺炎81例。山东中医杂志，1990，9(6)：12
56．段登志，前列回春胶囊的药理作用和临床应用浅析。云南中医杂志，1995，16(1)：5
57．朱普英，州都丸治疗前列腺增生78例临床观察。河北中医，1992，14(6)：8
58．农方，金匮肾气丸治疗前列腺肥大10例。云南中医杂志，1994，15(5)：13
59．贾士安，胡遵达主任医师治疗前列腺增生经验。中医药研究，1995，(2)：40
60．罗振华，梁乃津教授治疗前列腺增生经验。新中医，1996，28(12)：10
61．李松林，启癃汤保留灌肠治疗前列腺增生尿潴留35例。陕西中医，1997，18(4)：152
62．李鸿林，中药水煎坐浴治疗前列腺增生症34例。实用中医药杂志，1995，(1)：582
63．王峻，中药熏治前列腺增生78例疗效观察。四川中医，1995，(10)26
64．林祖贤，三七粉治疗前列腺肥大。实用中西结合杂志，1994，7(12)：753
65．王继贤，消痔灵局部注射治疗前列腺肥大。实用中医药杂志，1994，(3)：39
66．苗聘三，加味桂枝茯苓丸治疗前列腺肥大引起的尿潴留。河南中医，1984(3)，31
67．刘斌武，等。桂枝茯苓丸加味治疗癃闭。新中医，1990，22(3)：43
68．盛增秀，等。桂枝茯苓丸的临床应用。河北中医，1984，(4)：43
69．吴源生，“前通汤”治老年前列腺肥大50例小结。江西中医药，1987，18(6)：22
70．邹火根，等。癃闭散治疗前列腺增生症的临床观察和药理实验。中医杂志，1982，23(7)：29
71．石学敏主编，中医纲目外科·泌尿·男性生殖系统疾病。北京：人民日报出版社。1993：3018
72．李曰庆，等。中西医结合诊治男科病讲座第十五讲。中国农村医学 1993，21(9)：11
73．裘法祖主编，外科学·泌尿外科·泌尿系梗阻4版北京：人民卫生出版社1995，652-655
2． Berry SJ, Coffey DS, Walsh PC, et al: The development of human benigh prostatic hyperplasia with age. J. Urol 1984;132;474
3． Morrison AS: Risk factors for prostatic hypertrophy. Am. J. Epidemiol 1992;135:974
4． Choi J, Edward F, Benson MC. Cellular senescence: A novel mechanism in the development of BPH. J Urol, 1999,161 :Suppl 4,873．
5． Riddle DL. Ageing. A message from the Gonads. Nature, 1999,399:308-309．
6． Hsin H, Kenyon C.Signals from the reproductive system regulate the life span of C.elegans. Nature, 1999, 399: 362-366．
7． Prehn RT. On the prevention and therapy of prostate cancer by androgen administration. Cancer Res, 1999, 59: 4161-4164．
8． 鲍震美，细胞凋亡。中华泌尿外科杂志，1998, 19:751-754．
9． Green DR. Apoptotic pathway: the roads to ruin. Cell, 1998, 94:695-698．
10． Kroerner G, Zamzami N, Susin SA. Mitochondrial control of apoptosis. Immunol Today, 1997,18:44-51．
11． Susin SA, Lorenzo HK, Zamzami N, et al. Molecular characterization of niitochondrial apoptosis-inducing factor. Nature, 1999, 397:441-446．
12． Tamm I, Wang Y, Sausville E, et al. IAP family protein surviving inhibits caspase activity and apoptosis induced by Fas (CD95) , Bax, caspase and anticancer drugs. Cancer Res, 1998, 58:5315-5320．
13． Deveraux QL, Takahashi R, Salvesen GS, et al. X-linked IAP is a direct inhibitor of cell-death protease. Nature, 1997,388:300-304．
14． Marcelli M, Cunning ham GR, Walkup M, et al. Signal pathway activated during apoptosis of the prostate cancer cell lone LNCaP: Over expression of Caspase 7 as a new gene therapy strategy for prostate cancer. Cancer Res, 1999, 59:382-390．
15． Weinartner K, Ben Sasson SA, Stewart R, et al. Endothelial cell proliferation activity in BPH and prostate cancer, an in vitro model for assessment, J Urol, 1998,159:465-470．
16． Folkman J, Is tissue mass regulated by vascular endothelial cells? Prostate as the first evidence. Endocrinology, 1998, 139:441-442．
17． Nelson NJ. Angiogenesis research is on fast forward. J Natl Cancer Inst, 1999,91:820-822．
18． Colao A, Marzullo P, Ferone D, et al. Prostatic hyperplasia: an unknown feature of acromegaly. J Natl Cancer Inst, 1998,83:775-779．
19． Price DT. New concepts in alpha-receptor biology. Office Education of 94th Annual Meeting, AUA, 1999．
20． Kyprianou N, Litvak JP, Borkowski A, et al. Induction of prostate apoptosis by doxazosin in benign prostatic hyperplasia. J Urol, 1998, 159:1810-1815．
21． Lepor H, Williford WO, Barry MJ, et al. The efficacy of terazosin, finasteride of both in benign prostatic hyperplasia. Veterans affairs cooperative studies benign prostatic hyperplasia study group. N Engl J Med, 1996,335:533-539．
22． Hudson PB, Boake R, Trachtenberg J, et al. Efficiency of finasteride is maintained in patients with BPH treated for 5 years. Urology, 1999,53:690-695．
23． Me Connell JD, Bruskewitz R, Walsh P, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med, 1998,338:557-563．
24． Reddy PK, Wasserman NA, Berg P Zhang G, Kapoor DA: Patient selection predicts out-come following balloon dilatation of Prostate [abstract], J Urol 1991;145:362
25． Reddy PK, Wasserman NA, Gfameda F, Casfaneda-Zuniga WR: Balloon dilatation of the Prostate for treatment of benign hyperplasia. Urol Clin North Am 1998;15:529-535
26． Kitagiwa M, Furuse H, Fukuta K, et al. Int J Urol, 1998;5(2) : 152-156
27． Fabian KM: The intraprostatic partial catheter (Urologial spiral) in German.
Urology [A]1980;19:236-238
28．蔡淦：癃闭。中医内科学 张伯臾主编，上海：上海科学技术出版社 1985；239-244
29．Schneider HJ，植物类药物治疗良性前列增生 UrolB，1994，34：96[德]
30．Patevilch D，仙人掌治疗前列腺肥大，J Herb Spie Medplant，1993，2(1)：45
31．可用来治疗良性前列腺肥大的没药属植物提取物 [英]CPI(B)，1994，(9401)：98
32．用于治疗前列腺肥大的蓝棕属植物提取物[英] CPI(B)，1994，(9344)：103
33．何清湖，尿癃康对大鼠前列腺增生的影响。湖南中医药导报，1997，3(2-3)：61
34．余志红，复方前列宝抑制前列增生及抗炎作用的研究。数理医学杂志，1995，8(2)：137
35．彭培初，复方琥角片治疗前列腺增生症的临床实验研究。上海中医药杂志，1995，(1)：1
36．黄树刚，中药治疗前列腺肥大94例的性激素变化。南京中医学院学报，1994，10(2)：10
37．黄自强，金利油抑制前列腺增生及抗炎作用。中成药，1991，13(6)：27
38．杨文凯，前列宁对前列腺增生的影响及其抗炎作用的研究。中草药，1991，22(6)：261
39．宋杰云，消疬注射液的实验研究。中西医结合杂志，1990，(10)：616
40．柴瑞霁，柴浩然治疗前列腺肥大并发尿潴留的经验。山西中医，1995，11(3)：1
41．方铁生，虚实分证论治疗前列腺增生症150例。南京中医药大学学报，1997，13(4)：206
42．陈万年，从痰论证前列腺增生症57例。山东中医杂志，1995，14(10)：446
43．孙隼修，前列腺肥大从痰论治五法。江苏中医，1995，16(9)：15
44．张文林，活血化瘀法治疗前列腺增生及急性尿潴留258例，辽宁中医杂志，1995，22(6)：263
45．马华，癃闭通治疗老年前列腺增生临床疗效观察。中医药研究，1996，(4)：30
46．陈志强，补肾祛淤疗法治疗前列腺增生症82例。新中医，1995，(2)：19
47．王劲松，自拟癃闭汤治疗前列腺增生症50例。国医论坛，1997，12(1)：32
48．张云程，中药治疗前列腺增生症90例。成都中医学院学报，1991，(3)：16
49．吴敬农，“补敛提汤”治疗老年前列腺肥大症64例。江苏中医，1996，17(1)：17
50．朱晓明，益气导水汤治疗前列腺增生症40例。湖南中医学院学报，1996，16(2)：29
51．牛宝生，前列舒煎治疗前列腺增生症68例。河南中医，1997，17(4)：223
52．张庆好，启癃汤治疗老年前列肥大55例。新中医，1995，27(2)：23
53．石户则孝等。汉方最新治疗，1998：7(3)：253-258
54．关口由纪等。汉方最新治疗，1997；6(3)：283-286
55．王敬善，前列丸治疗前列腺增生症和慢性前列腺炎81例。山东中医杂志，1990，9(6)：12
56．段登志，前列回春胶囊的药理作用和临床应用浅析。云南中医杂志，1995，16(1)：5
57．朱普英，州都丸治疗前列腺增生78例临床观察。河北中医，1992，14(6)：8
58．农方，金匮肾气丸治疗前列腺肥大10例。云南中医杂志，1994，15(5)：13
59．贾士安，胡遵达主任医师治疗前列腺增生经验。中医药研究，1995，(2)：40
60．罗振华，梁乃津教授治疗前列腺增生经验。新中医，1996，28(12)：10
61．李松林，启癃汤保留灌肠治疗前列腺增生尿潴留35例。陕西中医，1997，18(4)：152
62．李鸿林，中药水煎坐浴治疗前列腺增生症34例。实用中医药杂志，1995，(1)：582
63．王峻，中药熏治前列腺增生78例疗效观察。四川中医，1995，(10)26
64．林祖贤，三七粉治疗前列腺肥大。实用中西结合杂志，1994，7(12)：753
65．王继贤，消痔灵局部注射治疗前列腺肥大。实用中医药杂志，1994，(3)：39
66．苗聘三，加味桂枝茯苓丸治疗前列腺肥大引起的尿潴留。河南中医，1984(3)，31
67．刘斌武，等。桂枝茯苓丸加味治疗癃闭。新中医，1990，22(3)：43
68．盛增秀，等。桂枝茯苓丸的临床应用。河北中医，1984，(4)：43
69．吴源生，“前通汤”治老年前列腺肥大50例小结。江西中医药，1987，18(6)：22
70．邹火根，等。癃闭散治疗前列腺增生症的临床观察和药理实验。中医杂志，1982，23(7)：29
71．石学敏主编，中医纲目外科·泌尿·男性生殖系统疾病。北京：人民日报出版社。1993：3018
72．李曰庆，等。中西医结合诊治男科病讲座第十五讲。中国农村医学 1993，21(9)：11
73．裘法祖主编，外科学·泌尿外科·泌尿系梗阻4版北京：人民卫生出版社1995，652-655